Brown Brothers Harriman & Co. Sells 20,795 Shares of Abbott Laboratories $ABT

Brown Brothers Harriman & Co. trimmed its stake in Abbott Laboratories (NYSE:ABT) by 1.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,687,424 shares of the healthcare product maker’s stock after selling 20,795 shares during the period. Abbott Laboratories comprises about 1.4% of Brown Brothers Harriman & Co.’s investment portfolio, making the stock its 19th largest position. Brown Brothers Harriman & Co. owned 0.10% of Abbott Laboratories worth $226,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chesapeake Capital Corp IL acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $390,000. FreeGulliver LLC acquired a new position in Abbott Laboratories in the third quarter valued at about $208,000. Jump Financial LLC bought a new stake in Abbott Laboratories during the third quarter worth about $3,048,000. Invenio Wealth Partners LLC raised its stake in shares of Abbott Laboratories by 7.5% in the third quarter. Invenio Wealth Partners LLC now owns 4,366 shares of the healthcare product maker’s stock valued at $585,000 after acquiring an additional 304 shares during the last quarter. Finally, Hutner Capital Management Inc. boosted its holdings in shares of Abbott Laboratories by 4.1% in the 3rd quarter. Hutner Capital Management Inc. now owns 43,162 shares of the healthcare product maker’s stock worth $5,781,000 after acquiring an additional 1,688 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ABT shares. Argus dropped their price target on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Royal Bank Of Canada decreased their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Barclays cut their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Citigroup reduced their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Price Performance

ABT opened at $107.99 on Friday. The company has a fifty day moving average price of $114.58 and a two-hundred day moving average price of $123.91. The firm has a market capitalization of $187.66 billion, a PE ratio of 29.03, a P/E/G ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Insider Transactions at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.